All questionsSafety: Nucala (mepolizumab), all indications5 questions · 2 sourcesWarningsWhat are the contraindications for Nucala?“NUCALA is contraindicated in patients with a history of hypersensitivity to mepolizumab or excipients in the formulation [see Warnings and Precautions (5.1), Description (11)].” (opens the source at this quote in a new tab)CopyFlagDoes Nucala affect parasitic worm infections?“Eosinophils may be involved in the immunological response to some helminth infections. Patients with known parasitic infections were excluded from participation in clinical trials. It is unknown if NUCALA will influence a patient’s response against parasitic infections. Treat patients with pre-existing helminth infections before initiating therapy with NUCALA. If patients become infected while receiving treatment with NUCALA and do not respond to anti-helminth treatment, discontinue treatment with NUCALA until infection resolves.” (opens the source at this quote in a new tab)CopyFlagSafetyDoes Nucala increase the risk of cancer?“Long-term animal studies have not been performed to evaluate the carcinogenic potential of mepolizumab. Published literature using animal models suggests that IL-5 and eosinophils are part of an early inflammatory reaction at the site of tumorigenesis and can promote tumor rejection. However, other reports indicate that eosinophil infiltration into tumors can promote tumor growth. Therefore, the malignancy risk in humans from an antibody to IL-5 such as mepolizumab is unknown.” (opens the source at this quote in a new tab)CopyFlagWhat happens after a Nucala overdose?“There is no specific treatment for an overdose with mepolizumab. If overdose occurs, the patient should be treated supportively with appropriate monitoring as necessary. Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.” (opens the source at this quote in a new tab)CopyFlagHow do I report Nucala side effects?“To report SUSPECTED ADVERSE REACTIONS, contact GSK at gsk.public.reportum.com or 1-888-825-5249 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.” (opens the source at this quote in a new tab)CopyFlag